keyword
https://read.qxmd.com/read/38432409/attention-deficit-hyperactivity-disorder-in-pregnancy-and-the-postpartum-period
#1
REVIEW
Olivia Scoten, Katarina Tabi, Vanessa Paquette, Prescilla Carrion, Deirdre Ryan, Nevena V Radonjic, Elizabeth A Whitham, Catriona Hippman
Attention-deficit/hyperactivity disorder (ADHD) is a childhood-onset neurodevelopmental disorder that frequently persists into adulthood, with 3% of adult women having a diagnosis of ADHD. Many women are diagnosed and treated during their reproductive years, resulting in management implications across pregnancy and postpartum. We know from clinical practice that ADHD symptoms frequently become challenging to manage during the perinatal period, requiring additional support and attention. There is often uncertainty among healthcare providers regarding the management of ADHD in the perinatal period, particularly the safety of pharmacotherapy for the developing fetus...
March 1, 2024: American Journal of Obstetrics and Gynecology
https://read.qxmd.com/read/38287140/association-of-patient-characteristics-and-insurance-type-with-anti-obesity-medications-prescribing-and-fills
#2
JOURNAL ARTICLE
Hamlet Gasoyan, Elizabeth R Pfoh, Rebecca Schulte, Erin Sullivan, Phuc Le, Michael B Rothberg
AIM: To characterize factors associated with the receipt of anti-obesity medication (AOM) prescription and fill. MATERIALS AND METHODS: This retrospective cohort study used electronic health records from 1 January 2015 to 30 June 2023, in a large health system in Ohio and Florida. Adults with a body mass index ≥30 kg/m2 who attended ≥1 weight-management programme or had an initial AOM prescription between 1 July 2015 and 31 December 2022, were included...
January 29, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37853655/commentary-on-foot-et-al-clinical-considerations-in-addressing-comorbid-stimulant-use-in-opioid-use-disorder
#3
JOURNAL ARTICLE
Matisyahu Shulman, Miranda Greiner, Adam Bisaga
No abstract text is available yet for this article.
October 18, 2023: Addiction
https://read.qxmd.com/read/37820077/treating-obesity-in-type-1-diabetes-mellitus-review-of-efficacy-and-safety
#4
REVIEW
Matthew Freeby, Kyrstin Lane
PURPOSE OF REVIEW: Obesity is an epidemic in the United States with serious concomitant co-morbid conditions; people living with type 1 diabetes mellitus (T1D) are not immune to the risk either. Weight gain in T1D is likely multifactorial, due to genetic, environmental and treatment-related factors. FDA-approved and other adjunctive weight loss therapies may benefit people living with T1D but there are risks to consider when providing recommendations or prescribing medications. RECENT FINDINGS: We performed a PubMed search of studies assessing clinical outcomes of both approved and off-label medications used in the treatment of type 1 diabetes...
February 1, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/37225553/obesity-prevalence-and-variability-in-management-practices-for-patients-with-symptomatic-peripheral-artery-disease
#5
JOURNAL ARTICLE
Lindsey E Scierka, Poghni A Peri-Okonny, Gaelle Romain, Carlos Mena-Hurtado, Kim G Smolderen
Obesity has been associated with poor disease outcomes in patients with lower extremity peripheral arterial disease (PAD). Given evolving treatments for obesity, evaluating its prevalence and treatment practices are key to develop a holistic management of PAD. We aimed to examine prevalence of obesity and variability of management strategies in symptomatic PAD patients enrolled in the international multicenter PORTRAIT registry from 2011 to 2015. Obesity management strategies studied included weight and/or dietary counseling and prescription of weight loss medications (orlistat, lorcaserin, phentermine-topiramate, naltrexone-buproprion, and liraglutide)...
May 22, 2023: Obesity Research & Clinical Practice
https://read.qxmd.com/read/37206494/bupropion-treatment-for-stimulant-withdrawal-in-a-patient-with-substance-use-disorder-and-unspecified-bipolar-disorder
#6
Daanish Y Khan, Bita C Behaeddin, Stepan Uhlyar, Jonathan M Parker
Patients presenting with comorbid stimulant use disorder is a common occurrence in nearly all medical specialties. New clinical strategies to care for patients experiencing stimulant withdrawal should be considered as an effort to improve clinical outcomes. Our patient, a woman in her early 20s with a history of substance use disorder and unspecified bipolar and related disorder, presented with acute psychosis with symptoms including agitation, auditory hallucinations, and delusions in the context of chronic mental illness and cocaine abuse...
April 2023: Curēus
https://read.qxmd.com/read/37007033/sales-trends-of-psychotropic-drugs-in-the-covid-19-pandemic-a-national-database-study-in-brazil
#7
JOURNAL ARTICLE
Fernando de Sá Del Fiol, Cristiane de Cássia Bergamaschi, Luciane Cruz Lopes, Marcus Tolentino Silva, Silvio Barberato-Filho
Background: The social restrictions among coronavirus disease 2019 (COVID-19) pandemic have posed a thoughtful risk to mental health and have implications in the use of drugs, including antidepressants, anxiolytics and other psychotropics. Objective: This study analyzed the sales data of the psychotropics prescribed in Brazil, in order to verify the change in consumption trends of these drugs during the COVID-19 pandemic. Methods: This interrupted time-series analyzed psychotropic sales data, between January 2014 and July 2021, using the National System of Controlled Products Management from The Brazilian Health Regulatory Agency...
2023: Frontiers in Pharmacology
https://read.qxmd.com/read/34023534/the-role-of-uptake-and-degradation-in-the-regulation-of-peripheral-serotonin-dynamics-in-gulf-toadfish-opsanus-beta
#8
JOURNAL ARTICLE
John Sebastiani, M Danielle McDonald
The neurotransmitter serotonin (5-hyroxytryptamine, 5-HT) is involved in a variety of peripheral processes. Arguably most notable is its role as a circulating vasoconstrictor in the plasma of vertebrates. Plasma 5-HT is maintained at constant levels under normal conditions through the processes of cellular uptake, degradation, and excretion, known collectively as clearance. However, the degree to which each individual component of clearance contributes to this whole animal response remains poorly understood...
August 2021: Comparative Biochemistry and Physiology. Part A, Molecular & Integrative Physiology
https://read.qxmd.com/read/33982032/differential-impact-on-isolated-rem-sleep-without-atonia-by-varying-antidepressant-therapies
#9
JOURNAL ARTICLE
John Feemster, Erik K St Louis, R Robert Auger
Background: REM sleep without atonia (RSWA) is characterized by increased phasic or tonic muscle activity in electromyography channels during polysomnography and usually causes REM sleep behaviour disorder, but RSWA also exists within healthy populations without dream-enactment behaviour, especially in psychiatric populations receiving antidepressant therapies. Evidence for differential impact of antidepressants on RSWA, and whether RSWA persists or resolves following changes in antidepressant therapy, remains limited...
December 2020: Journal of affective disorders reports
https://read.qxmd.com/read/33962014/pharmacotherapy-of-obesity-an-update
#10
REVIEW
Andrea Cignarella, Luca Busetto, Roberto Vettor
Several pharmacological approaches to controlling body weight have been developed over the last decades, albeit with limited success. Currently available agents include centrally acting appetite suppressants and peripherally acting compounds. Efficacy and safety of these agents in the clinical setting require a difficult balance. Further strategies including multiagonists able to simultaneously target multiple actors involved in obesity initiation and expansion such as the glucagon receptor family are under investigation...
July 2021: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://read.qxmd.com/read/32459054/the-association-of-comt-genotype-with-buproprion-treatment-response-in-the-treatment-of-major-depressive-disorder
#11
JOURNAL ARTICLE
Jay Fawver, Mindy Flanagan, Thomas Smith, Michelle Drouin, Michael Mirro
BACKGROUND: Pharmacodynamics and pharmacogenetics are being explored in pharmacological treatment response for major depressive disorder (MDD). Interactions between genotype and treatment response may be dose dependent. In this study, we examined whether MDD patients with Met/Met, Met/Val, and Val/Val COMT genotypes differed in their response to bupropion in terms of depression scores. METHODS: This study utilized a convenience sample of 241 adult outpatients (≥18 years) who met DSM-5 criteria for MDD and had visits at a Midwest psychopharmacology clinic between February 2016 and January 2017...
July 2020: Brain and Behavior
https://read.qxmd.com/read/32344790/targeted-intervention-to-reduce-smoking-among-people-with-severe-mental-illness-implementation-of-a-smoking-cessation-intervention-in-an-inpatient-mental-health-setting
#12
JOURNAL ARTICLE
Julia M Lappin, Dennis Thomas, Jackie Curtis, Stephen Blowfield, Mike Gatsi, Gareth Marr, Ryan Courtney
Background and Objectives: Smoking and smoking-related harms are highly prevalent among people with severe mental illness. Targeted smoking cessation programs are much needed in this population. This pilot study aimed to assess the effectiveness of implementing smoking cessation system change interventions within an acute inpatient mental health unit. Materials and Methods: Design: Pre-post intervention study. System change interventions for smoking cessation were delivered over a three-month period (05 March 2018-04 June 2018) on an acute inpatient mental health unit...
April 24, 2020: Medicina
https://read.qxmd.com/read/32212940/bupropion-associated-seizures-following-acute-overdose-who-develops-late-seizures
#13
MULTICENTER STUDY
Steve Offerman, Jasmin Gosen, Stephen H Thomas, Angie Padilla-Jones, Anne-Michelle Ruha, Michael Levine
Objectives: Bupropion is an antidepressant that is commonly known to cause seizures in overdose. Because of concern for delayed onset of seizures, patients are frequently observed for prolonged periods after overdose. The primary objective is to evaluate the incidence and clinical parameters associated with late seizures following bupropion overdose. Methods: This retrospective study of acute bupropion overdose who presented to 26 different hospitals in California and Arizona during an 8 year time period...
December 2020: Clinical Toxicology
https://read.qxmd.com/read/31591807/poor-initiation-of-smoking-cessation-therapies-in-hospitalised-patients-with-copd-is-associated-with-low-levels-of-formal-training-amongst-hospital-doctors-and-under-utilisation-of-nursing-lead-interventions
#14
JOURNAL ARTICLE
J Pham, S Pitney, D Sweeney, C Reekie, N Harkness
BACKGROUND: Smoking cessation intervention is a key component in the management of chronic obstructive pulmonary disease (COPD). AIMS: The aim of this study was to evaluate the prescribing of smoking cessation therapies (SCT) amongst hospital clinicians and identify factors that may hinder delivery of effective interventions. METHODS: A retrospective analysis of medical records of patients admitted to the Royal Hobart Hospital with an acute exacerbation of COPD was performed...
October 7, 2019: Internal Medicine Journal
https://read.qxmd.com/read/31528087/new-era-endoscopic-treatment-options-in-obesity-a-paradigm-shift
#15
REVIEW
Jason Glass, Ahson Chaudhry, Muhammad S Zeeshan, Zeeshan Ramzan
The prevalence of obesity continues to rise, and along with it comes a multitude of health-related consequences. The healthcare community has consistently struggled with providing treatment options to obese patients, in part due to the reluctance of patients in pursuing the more effective (yet invasive) surgical approaches such as sleeve gastrectomy and Rou-en-Y gastric bypass. On the other hand, the less invasive approach such as lifestyle/behavioral interventions and pharmacotherapy (Orlistat, Phenteramine, Phentermine/Topiramate, Locaserin, Naltrexon/Buproprion, and Liraglutide) have very limited efficacy, especially in the morbidly obese patients...
August 28, 2019: World Journal of Gastroenterology: WJG
https://read.qxmd.com/read/30058889/obesity-management-among-patients-with-type-2-diabetes-and-prediabetes-a-focus-on-lifestyle-modifications-and-evidence-of-antiobesity-medications
#16
JOURNAL ARTICLE
Bao Nguyen, Jennifer Clements
The prevalence of obesity has increased over the past three decades in the United States and worldwide. This article reviews landmark trials for lifestyle modifications as well as clinical evidence and implications for locaserin, phentermine with topiramate, buproprion with naltrexone, and liraglutide in patients with type 2 diabetes and obesity. Areas covered: A MEDLINE search, from 1970 to May 2017, was conducted using key search terms - lifestyle modifications, antiobesity medication, obesity and diabetes...
September 2017: Expert Review of Endocrinology & Metabolism
https://read.qxmd.com/read/29955810/can-e-cigarettes-and-pharmaceutical-aids-increase-smoking-cessation-and-reduce-cigarette-consumption-findings-from-a-nationally-representative-cohort-of-american-smokers
#17
JOURNAL ARTICLE
Tarik Benmarhnia, John P Pierce, Eric Leas, Martha M White, David R Strong, Madison L Noble, Dennis R Trinidad
Many smokers believe that electronic nicotine delivery systems (ENDS) and pharmaceutical cessation aids can help them quit smoking or reduce cigarette consumption, but the evidence for e-cigarettes to aid quitting is limited. Examining 3,093 quit attempters in the nationally representative US Population Assessment of Tobacco and Health (PATH) Study, using data from 2013-2015, we evaluated the influence of ENDS and pharmaceutical cessation aids on persistent abstinence (≥30 days) from cigarettes and reduced cigarette consumption, using propensity score matching to balance comparison groups on potential confounders and multiple imputation to handle missing data...
November 1, 2018: American Journal of Epidemiology
https://read.qxmd.com/read/29579233/systematic-review-and-meta-analysis-to-assess-the-safety-of-bupropion-and-varenicline-in-pregnancy
#18
JOURNAL ARTICLE
Emily Turner, Matthew Jones, Luis R Vaz, Tim Coleman
INTRODUCTION: Smoking in pregnancy is a substantial public health issue, but, apart from nicotine replacement therapy (NRT), pharmacological therapies are not generally used to promote cessation. Bupropion and varenicline are effective cessation methods in nonpregnant smokers and this systematic review investigates their safety in pregnancy. METHODS: We searched MEDLINE, EMBASE, CINAHL, and PsychINFO databases for studies of any design reporting pregnancy outcomes after bupropion or varenicline exposure...
July 17, 2019: Nicotine & Tobacco Research
https://read.qxmd.com/read/29151591/us-health-policy-and-prescription-drug-coverage-of-fda-approved-medications-for-the-treatment-of-obesity
#19
JOURNAL ARTICLE
G Gomez, F C Stanford
OBJECTIVE: Obesity is now the most prevalent chronic disease in the United States, which amounts to an estimated $147 billion in health care spending annually. The Affordable Care Act (ACA) enacted in 2010 included provisions for private and public health insurance plans that expanded coverage for lifestyle/behavior modification and bariatric surgery for the treatment of obesity. Pharmacotherapy, however, has not been included despite their evidence-based efficacy. We set out to investigate the coverage of Food and Drug Administration-approved medications for obesity within Medicare, Medicaid and ACA-established marketplace health insurance plans...
March 2018: International Journal of Obesity
https://read.qxmd.com/read/28326291/applying-a-new-theory-to-smoking-cessation-case-of-multi-theory-model-mtm-for-health-behavior-change
#20
JOURNAL ARTICLE
Manoj Sharma, Jagdish Khubchandani, Vinayak K Nahar
Background: Smoking continues to be a public health problem worldwide. Smoking and tobacco use are associated with cardiovascular diseases that include coronary heart disease, atherosclerosis, cerebrovascular disease, and abdominal aortic aneurysm. Programs for quitting smoking have played a significant role in reduction of smoking in the United States. The smoking cessation interventions include counseling, nicotine replacement therapy, buproprion therapy, and varenicline therapy. The success rates with each of these approaches vary with clear need for improvement...
2017: Health Promotion Perspectives
keyword
keyword
22034
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.